Medical treatment of juvenile idiopathic arthritis

被引:210
|
作者
Hashkes, PJ
Laxer, RM
机构
[1] Cleveland Clin Fdn, Dept Rheumat Dis, Sect Pediat Rheumatol, Cleveland, OH 44195 USA
[2] Hosp Sick Children, Dept Clin & Acad Affairs, Toronto, ON M5G 1X8, Canada
[3] Univ Toronto, Dept Pediat & Med, Toronto, ON, Canada
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2005年 / 294卷 / 13期
关键词
D O I
10.1001/jama.294.13.1671
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The treatment of-juvenile idiopathic arthritis (JIA) has changed markedly in the last 15 years. Many children with JIA are not treated by pediatric rheumatologists. Objective To review the best evidence for the treatment of JIA. Data Sources English-language trials of JIA between 1966 and 2005 were searched using MEDLINE, EMBASE, the Cochrane database, and abstracts from recent rheumatology and pediatric scientific meetings. Study Selection Randomized controlled trials and-open studies including at least 10 patients for medications without controlled trials. Data Extraction For studies after 1997, the American College of Rheumatology Pediatric 30 outcome measure was used to define patients as responders. For older studies, the primary response outcome measure defined by the authors was used. Data Synthesis Thirty-four controlled studies were identified. Nonsteroidal anti-inflammatory drugs are effective only for a minority of patients, mainly those with oligoarthritis. Intra-articular corticosteroid injections are very effective for oligoarthritis. Methotrexate is effective for the treatment of extended oligoarthritis And polyarthritis and less effective for systemic arthritis. Sulfasalazine and leflunomide may be alternatives to methotrexate. Antitumor necrosis factor medications are highly effective for polyarticular course JIA not responsive to methotrexate but are less effective in systemic arthritis. There is a lack of evidence for the optimal treatment of systemic and enthesitis-related arthritis. Conclusions Despite many advances in the treatment of AA, there is still a lack of evidence for treatment of several disease subtypes. The treatment plan needs to be individualized based on the JIA subtype.
引用
收藏
页码:1671 / 1684
页数:14
相关论文
共 50 条
  • [41] Canakinumab for the treatment of systemic juvenile idiopathic arthritis
    Grom, Alexei A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (11) : 1427 - 1435
  • [42] Safety of tocilizumab in the treatment of juvenile idiopathic arthritis
    Machado, Sandra Helena
    Xavier, Ricardo Machado
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 493 - 500
  • [43] Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis
    Bou, Rosa
    Iglesias, Estibaliz
    Anton, Jordi
    CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (08)
  • [44] Treatment of juvenile idiopathic arthritis: a revolution in care
    Matthew L Stoll
    Randy Q Cron
    Pediatric Rheumatology, 12
  • [45] NEW AGENTS FOR THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS
    Wouters, Carine H.
    CURRENT ALLERGY & CLINICAL IMMUNOLOGY, 2010, 23 (03) : 104 - 109
  • [46] Update on the pathogenesis and treatment of juvenile idiopathic arthritis
    Giancane, Gabriella
    Alongi, Alessandra
    Ravelli, Angelo
    CURRENT OPINION IN RHEUMATOLOGY, 2017, 29 (05) : 523 - 529
  • [47] Adalimumab in the Treatment of Uveitis in Juvenile Idiopathic Arthritis
    Thorne, Jennifer E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17): : 1682 - 1683
  • [48] Advances in immunosuppressive treatment of juvenile idiopathic arthritis
    Horneff, G
    TREATMENT OF AUTOIMMUNE DISORDERS, 2003, : 59 - 71
  • [49] Treatment of Juvenile Idiopathic Arthritis in the Biologics Era
    Haas, J. -P.
    AKTUELLE RHEUMATOLOGIE, 2015, 40 (04) : 275 - 279
  • [50] Evolution of treatment options for juvenile idiopathic arthritis
    Ren, Tao
    Guan, Jia-Hui
    Li, Yu
    Li, Nan-Nan
    Li, Zheng
    WORLD JOURNAL OF ORTHOPEDICS, 2024, 15 (09):